...of cash and stock. Pantarhei is also eligible for milestones. The JV was formed by Pantarhei...
...Phase III development of the human fetal estrogen and plans to launch Estelle in 2018. Pantarhei...
...women with breast cancer and endometriosis. Estetrol is in Phase II testing for the indications. Pantarhei Bioscience B.V....

...to dose-dependent, significant reductions in the number and growth of tumors vs. vehicle-treated controls (p<0.01). Pantarhei...
...osteoporosis. Data were published in the Journal of Hormone and Molecular Biology and Clinical Investigation. Pantarhei Bioscience B.V....

...Data were presented at the European Society of Contraception meeting in The Hague, the Netherlands. Pantarhei...
...Pill-Plus for oral use in the U.S. from BioSante. BioSante Pharmaceuticals Inc. (NASDAQ:BPAX), Lincolnshire, Ill. Pantarhei Bioscience B.V....

...testosterone levels to the normal range of 1.3 to 8.0 pg/mL for premenopausal healthy women. Pantarhei...
...develop and commercialize Pill-Plus in the U.S. from BioSante. BioSante Pharmaceuticals Inc. (NASDAQ:BPAX), Lincolnshire, Ill. Pantarhei Bioscience B.V....

...rights to the agent to Pantarhei earlier this year. BioSante Pharmaceuticals Inc. (BPA), Lincolnshire, Ill. Pantarhei Bioscience B.V....